Alfieri Michael

PFO Alfieri buys 5,000 ALDX shares at $1.42; stock now $1.83, down -73.5% from 52-week high, company unprofitable.

Alfieri Michael, Principal Financial Officer, purchased 5,000 shares of Aldeyra Therapeutics at $1.42 on 2026-03-18, tripling his holdings from 2,500 to 7,500 shares. The purchase occurred in a severely depressed environment: the stock is currently priced at $1.83, down -73.5% from its 52-week high of $6.91 and down -64.5% over the trailing 30 days. The company reported a net loss of $-7,688,341.00 for its most recent fiscal year. Alfieri's prior buy at this ticker on 2025-08-13 returned -1.3% over 90 days, and his cross-ticker track record shows a 0.00% win rate over 90-day holding periods. The transaction's modest absolute value ($7,100.00) and the insider's poor prior timing history at this stock suggest this purchase does not constitute evidence of conviction-driven accumulation.

PFO Michael Alfieri buys 2,500 shares of ALDX at $5.30; first position after company losses of $-9.8M

Principal Financial Officer Michael Alfieri initiated a position of 2,500 shares at $5.30 on 2025-08-13, his first shareholding in the company. This purchase occurs while Aldeyra Therapeutics remains unprofitable with net income of $-9.8M over the most recent full fiscal year. The stock has declined 22.8% from its 52-week high of $6.98 yet has appreciated 149.5% over the past 90 days and 4.5% over 30 days, suggesting recent positive momentum despite the company's ongoing losses. As the principal financial officer, Alfieri's initial buy carries potential relevance to capital allocation decisions, though the modest position size of 2,500 shares warrants context about company magnitude and officer compensation structures.